C12N 2760/18071
Demonstrated in vivo effect
C12N2760/18071 (Demonstrated in vivo effect) appears on 6 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 14
- Assignees
- 8
- Inventors
- 18
- Latest grant
- 6 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 4 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
| 2020 | 0 | 1 |
| 2021 | 0 | 1 |
| 2022 | 2 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of vaccine administration6 May 2025US 12,290,559 B2Zoetis Services LLC
- Methods of vaccine administration13 Dec 2022US 11,524,067 B2Zoetis Services LLC
- Methods of vaccine administration13 Dec 2022US 11,524,068 B2Zoetis Services LLC
- Compositions and methods comprising hydrocarbon-stapled polypeptides16 Apr 2019US 10,259,848 B2Dana-Farber Cancer Institute, Inc.
- Dry formulations of vaccines that are room temperature stable12 Dec 2017US 9,839,613 B2Intervet Inc.
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Recombinant live attenuated rsv vaccine strain and production method therefor24 Apr 2025US 2025/0127872 A1SK Bioscience Co., Ltd.
- Methods Of Vaccine Administration16 Mar 2023US 2023/0078668 A1Zoetis Services LLC
- Fusion protein16 Dec 2021US 2021/0386850 A1
- Methods Of Vaccine Administration8 Oct 2020US 2020/0316192 A1Zoetis Services LLC
Most cited
By later US patents
- Compositions and methods for the treatment of viral infections5US 9,290,545 B2Dana-Farber Cancer Institute, Inc. · 2016
- Dry formulations of vaccines that are room temperature stable5US 9,839,613 B2Intervet Inc. · 2017
- Compositions and methods comprising hydrocarbon-stapled polypeptides4US 10,259,848 B2Dana-Farber Cancer Institute, Inc. · 2019